Agreement to facilitate access to Chinese market for European companies

The alliance of main health clusters in Europe, bioXclusters plus, promoted by the regions of Catalonia (Biocat), Bavaria (Bio^M), Piedmont (bioPmed) and Auvergne-Rhône-Alpes (Lyonbiopole), has signed an agreement with Fenglin Biomedical Center (part of the Fenglin Group) to offer free advisory and professional services for small and medium-sized companies interested in operating in China.

This deal, signed under the framework of a bioXclusters plus mission to Shanghai for the Sino-Euro Bio Partnering conference on 15 and 16 May, includes guidance regarding market access, private investment, clinical trials and soft-landing packages for any innovative companies in the bioXclusters plus regions, including the BioRegion of Catalonia.

Fenglin Biomedical Center is an innovation platform in Xuhui Shanghai that works to help foreign biomedical companies land in the country. It is part of the Fenglin Group, which owns four large biomedical parks in the Shanghai area, including Juke Park and the Shanghai Fenglin Life Healthcare Park.

The platform has work spaces and helps companies boost their value on the market with professional services. It mobilizes the resources of universities, hospitals, industry and private investors in the region, in addition to bringing together important companies. The agreement reached with bioXclusters plus will benefit, above all, companies working in personalized medicine. This, according to Biocat Head of Internationalization Roi Villar, is due to the fact that the Chinese market is increasingly attractive to European companies innovating in this field.

Companies interested in benefiting from this agreement can contact their local bioXclusters plus members for more information. Companies in the BioRegion can contact Roi Villar (rvillar@biocat.cat).